Autor(es): Serrenho, Inês ; Cardoso, Carla M. ; Grãos, Mário ; Dinis, Alexandra ; Manadas, Bruno ; Baltazar, Graça
Data: 2022
Identificador Persistente: https://hdl.handle.net/10316/114897
Origem: Estudo Geral - Universidade de Coimbra
Assunto(s): neonatal hypoxic-ischemic encephalopathy; umbilical cord blood cells; cell therapy; therapeutic hypothermia; neonatal brain injury; Rats; Animals; Neuroprotection; Fetal Blood; Ischemia; Hypothermia; Hypoxia-Ischemia, Brain; Hypothermia, Induced
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of death and long-term disability in the perinatal period. Currently, therapeutic hypothermia is the standard of care for this condition with modest efficacy and strict enrollment criteria. Therapy with umbilical cord blood cells (UCBC) has come forward as a strong candidate for the treatment of neonatal HIE, but no preclinical studies have yet compared the action of UCBC combined with hypothermia (HT) with the action of each therapy by itself. Thus, to evaluate the potential of each therapeutic approach, a hypoxic-ischemic brain lesion was induced in postnatal day ten rat pups; two hours later, HT was applied for 4 h; and 24, 48, and 72 h post-injury, UCBC were administered intravenously. The neonatal hypoxic-ischemic injury led to a brain lesion involving about 48% of the left hemisphere that was not improved by HT (36%) or UCBC alone (28%), but only with the combined therapies (25%; p = 0.0294). Moreover, a decrease in glial reactivity and improved functional outcomes were observed in both groups treated with UCBC. Overall, these results support UCBC as a successful therapeutic approach for HIE, even when treatment with therapeutic hypothermia is not possible.
